FITC/ PE - anti Human CD3/CD19 - 33-2A3, A3-B1

Reference Size Price Quantity Add to cart
3F119PE1-50T 50 test
231,00 €

Product Description

  • 33-2A3, A3-B1
  • IgG2a, IgG2a
  • FCM
  • FITC/ PE
  • Human
  • PBS, 0,09% sodium Azide, may contain carrier protein-stabilizer
  • IVD-CE
CD3/CD19 View larger

Antigen details

Reactivity: The CD3 monoclonal antibody is directed against the CD3- antigen (T3-antigen), which is expressed on human T lymphocytes. The monoclonal antibody reacts with 80-90% human peripheral T lymphocytes and medullary thymocytes. The monoclonal antibody does not react with B-cells, monocytes, granulocytes and platelets. The monoclonal antibody is mitogenic for resting T lymphocytes and it blocks the cytolytic activity of CTL clones.

The CD19- antigen (B4-antigen), which is expressed on human B lymphocytes. The monoclonal antibody is B lineage-specific and reacts with early B-cell precursors, pre-pre-B-cells, pre-B- cells, B-cells, intermediate B-cells, mature B-cells and some plasmacytoid cells. Plasma cells were found to be negative. The monoclonal antibody does not react with other haemopoïetic cells. The monoclonal antibody also reacts with pre-B-cell- lines, B lymphoblastoid cell-lines and Burkitt cell- lines, and with 50% of myeloma cell-lines. Virtually all non T-ALL, B-CLL and B-cell lymphomas were found to be positive, myeloma cells were found to be negative.

Specificity: The CD3 antibody recognizes 22/26/30 kD MW lymphocyte surface molecules associated with the T cell antigen receptor complex. Reacts with 85% of peripheral blood T lymphocytes, 70% of thymocytes, the majority of T cell chronic lymphocytic leukaemias, Sezary leukaemias and approximately 70% of acute lymphoblastic leukaemias of T cell origin.

 

The CD19 antibody recognizes 90-95 Kd MW lymphocyte surface antigen identified by monoclonal antibodies belonging to the CD19 cluster. Expressed from the earliest stages of B-progenitor development and on all peripheral B cells including germinal centre B cells, all B cell lines tested and B cell leukaemias tested. The antigen is lost on B cell maturation to plasma cells.

The CD3 monoclonal antibody is directed against the CD3- antigen (T3-antigen), which is expressed on human T lymphocytes. The monoclonal antibody reacts with 80-90% human peripheral T lymphocytes and medullary thymocytes. The monoclonal antibody does not react with B-cells, monocytes, granulocytes and platelets. The monoclonal antibody is mitogenic for resting T lymphocytes and it blocks the cytolytic activity of CTL clones.

Clinical applications: T and B lymphocytes are used to characterize and monitor some forms of immunodeficiency and autoimmune diseases